Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FlutiForm versus fluticasone inhalers in moderate to severe asthma
2007-005653-37Phase 3
Key facts
- Status
- Terminated
- Start
- Dec 2007
- Countries
- 1
- Sponsor
- Skyepharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Conditions
- asthma
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate + formoterol and fluticasone propionate in asthma (3 arms), sponsored by Skyepharma. Started Dec 2007; status: terminated.
02
Design
3 arms- Study design
- RandomizedDouble-blind
FlutiForm combination inhaler
Fluticasone propionate + formoterol fumarate combination inhaler twice daily.
SKP fluticasone inhaler
Fluticasone propionate monotherapy inhaler twice daily.
Flovent HFA inhaler
Commercial fluticasone propionate monotherapy inhaler twice daily.
03
Who it enrols
Adolescents and adults aged 12 years or older with moderate to severe asthma were eligible. Patients with recent life-threatening or near-fatal asthma, asthma-related hospitalization or intubation within the past year, or emergency room visit for asthma within the prior 3 months were excluded.
Beyond the preview
Go deeper on 2007-005653-37.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005653-37.